[
  {
    "ts": "2026-02-18T11:00:19+00:00",
    "headline": "US stocks are off to their worst start versus the global market since 1995",
    "summary": "As US valuations and price-to-earnings ratios have surged, global markets have outperformed the S&P 500.",
    "url": "https://finance.yahoo.com/news/us-stocks-are-off-to-their-worst-start-versus-the-global-market-since-1995-110019152.html",
    "source": "Yahoo Finance",
    "provider": "yfinance",
    "raw": {
      "id": "ef0a2c7e-4c7e-4826-8172-a9dd74544189",
      "content": {
        "id": "ef0a2c7e-4c7e-4826-8172-a9dd74544189",
        "contentType": "STORY",
        "title": "US stocks are off to their worst start versus the global market since 1995",
        "description": "",
        "summary": "As US valuations and price-to-earnings ratios have surged, global markets have outperformed the S&P 500.",
        "pubDate": "2026-02-18T11:00:19Z",
        "displayTime": "2026-02-18T11:00:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-02/4745e1b0-0903-11f1-bbfe-a0582ad6bb74",
          "originalWidth": 4784,
          "originalHeight": 3190,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QIvWF6J6kzAG2NSBSvVoPw--~B/aD0zMTkwO3c9NDc4NDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-02/4745e1b0-0903-11f1-bbfe-a0582ad6bb74.cf.webp",
              "width": 4784,
              "height": 3190,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VpRa2Qjoj11ypp4gz989Tw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-02/4745e1b0-0903-11f1-bbfe-a0582ad6bb74.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance",
          "url": "http://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/us-stocks-are-off-to-their-worst-start-versus-the-global-market-since-1995-110019152.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/us-stocks-are-off-to-their-worst-start-versus-the-global-market-since-1995-110019152.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "ACWX"
            },
            {
              "symbol": "APO"
            },
            {
              "symbol": "DX-Y.NYB"
            },
            {
              "symbol": "AVGO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "V"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T10:32:55+00:00",
    "headline": "XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500",
    "summary": "Healthcare isn’t going anywhere. An aging population, chronic disease management, and breakthrough treatments ensure this sector remains essential regardless of market conditions. Health Care Select Sector SPDR Fund (NYSEARCA:XLV) offers concentrated exposure to this defensive sector, but with concentration comes tradeoffs investors must understand before allocating capital. Pure Healthcare Exposure With Mega-Cap Anchors XLV functions ... XLV is A $41 Billion Defensive Healthcare Play That Looks",
    "url": "https://247wallst.com/investing/2026/02/18/xlv-is-a-41-billion-defensive-healthcare-play-that-looks-good-until-you-compare-to-the-sp-500/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "86e0edc5-c207-39dd-aaba-6769f2d97f86",
      "content": {
        "id": "86e0edc5-c207-39dd-aaba-6769f2d97f86",
        "contentType": "STORY",
        "title": "XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500",
        "description": "",
        "summary": "Healthcare isn’t going anywhere. An aging population, chronic disease management, and breakthrough treatments ensure this sector remains essential regardless of market conditions. Health Care Select Sector SPDR Fund (NYSEARCA:XLV) offers concentrated exposure to this defensive sector, but with concentration comes tradeoffs investors must understand before allocating capital. Pure Healthcare Exposure With Mega-Cap Anchors XLV functions ... XLV is A $41 Billion Defensive Healthcare Play That Looks",
        "pubDate": "2026-02-18T10:32:55Z",
        "displayTime": "2026-02-18T10:32:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/f4e0726dddf55916b1b34f9dcc2d4446",
          "originalWidth": 1366,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IgC6HfL8FtUwNbKCRAjPOQ--~B/aD03Njg7dz0xMzY2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/f4e0726dddf55916b1b34f9dcc2d4446.cf.webp",
              "width": 1366,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kXpSTrapkjD7wcFAONghGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/f4e0726dddf55916b1b34f9dcc2d4446.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/02/18/xlv-is-a-41-billion-defensive-healthcare-play-that-looks-good-until-you-compare-to-the-sp-500/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/xlv-41-billion-defensive-healthcare-103255420.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "UNH"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "XLV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T11:45:00+00:00",
    "headline": "Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition. At 36 weeks, treatment with Taltz and Zepbound met the primary and all key secondary endpoints, delivering superio",
    "url": "https://finance.yahoo.com/news/lillys-taltz-ixekizumab-zepbound-tirzepatide-114500159.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "a244c5a6-45ee-3354-89e3-5b5a262febea",
      "content": {
        "id": "a244c5a6-45ee-3354-89e3-5b5a262febea",
        "contentType": "STORY",
        "title": "Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition. At 36 weeks, treatment with Taltz and Zepbound met the primary and all key secondary endpoints, delivering superio",
        "pubDate": "2026-02-18T11:45:00Z",
        "displayTime": "2026-02-18T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lillys-taltz-ixekizumab-zepbound-tirzepatide-114500159.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lillys-taltz-ixekizumab-zepbound-tirzepatide-114500159.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T12:22:00+00:00",
    "headline": "Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition?",
    "summary": "Lilly is advancing next-gen obesity drugs like oral orforglipron and retatrutide as competition heats up.",
    "url": "https://finance.yahoo.com/news/llys-next-gen-obesity-pipeline-122200037.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "9ee51842-5fc4-301c-b235-e9f0ea04e174",
      "content": {
        "id": "9ee51842-5fc4-301c-b235-e9f0ea04e174",
        "contentType": "STORY",
        "title": "Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition?",
        "description": "",
        "summary": "Lilly is advancing next-gen obesity drugs like oral orforglipron and retatrutide as competition heats up.",
        "pubDate": "2026-02-18T12:22:00Z",
        "displayTime": "2026-02-18T12:22:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JLDGQt80ARh3qkafoo9TaA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ncdWYZW_rP_HUKWXjdodfA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/llys-next-gen-obesity-pipeline-122200037.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/llys-next-gen-obesity-pipeline-122200037.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T15:21:45+00:00",
    "headline": "J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push",
    "summary": "Feb 18 (Reuters) - Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale",
    "url": "https://finance.yahoo.com/news/j-j-invest-1-billion-152145560.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "5178d860-ca8d-31f4-9802-9328a5504996",
      "content": {
        "id": "5178d860-ca8d-31f4-9802-9328a5504996",
        "contentType": "STORY",
        "title": "J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push",
        "description": "",
        "summary": "Feb 18 (Reuters) - Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale",
        "pubDate": "2026-02-18T15:21:45Z",
        "displayTime": "2026-02-18T15:21:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/7d28972b448cced4f4cefed8732e1f0f",
          "originalWidth": 800,
          "originalHeight": 571,
          "caption": "A Johnson & Johnson banner is displayed on the front of the New York Stock Exchange (NYSE) in New York City, in New York City, U.S., December 5, 2023.  REUTERS/Brendan McDermid",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PbUe6vH2FHz0.60wTkOl8g--~B/aD01NzE7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/7d28972b448cced4f4cefed8732e1f0f.cf.webp",
              "width": 800,
              "height": 571,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KJkB67QvnWtzG2Sy_CtaKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/7d28972b448cced4f4cefed8732e1f0f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/j-j-invest-1-billion-152145560.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-invest-1-billion-152145560.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T15:13:51+00:00",
    "headline": "Eli Lilly and Company (LLY) Gains as Medicare Expansion of GLP-1 Weight Loss Drugs Eases Pricing Concerns",
    "summary": "Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can be downloaded here. The fund reported that equity markets remained volatile during the quarter amid concerns over elevated valuations and financing for large-scale data center investments, although the portfolio modestly outperformed the Russell 1000 benchmark […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-gains-151351405.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "fc6c85c4-2f6e-3caa-b4d0-68ce3cccda5a",
      "content": {
        "id": "fc6c85c4-2f6e-3caa-b4d0-68ce3cccda5a",
        "contentType": "STORY",
        "title": "Eli Lilly and Company (LLY) Gains as Medicare Expansion of GLP-1 Weight Loss Drugs Eases Pricing Concerns",
        "description": "",
        "summary": "Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can be downloaded here. The fund reported that equity markets remained volatile during the quarter amid concerns over elevated valuations and financing for large-scale data center investments, although the portfolio modestly outperformed the Russell 1000 benchmark […]",
        "pubDate": "2026-02-18T15:13:51Z",
        "displayTime": "2026-02-18T15:13:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/51b1364b09f7f643bbc0d7710846eb01",
          "originalWidth": 847,
          "originalHeight": 565,
          "caption": "Eli Lilly and Company (LLY) Gains as Medicare Expansion of GLP-1 Weight Loss Drugs Eases Pricing Concerns",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0kVV1gNCVVOZDpsioIH4cA--~B/aD01NjU7dz04NDc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/51b1364b09f7f643bbc0d7710846eb01.cf.webp",
              "width": 847,
              "height": 565,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BHDCEBkkB7gyj5Wp_6vnrA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/51b1364b09f7f643bbc0d7710846eb01.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-gains-151351405.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-gains-151351405.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T13:12:00+00:00",
    "headline": "Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026?",
    "summary": "RIGL's 2025 sales jump 60% to $232M, led by Tavalisse. With 2026 product sales seen at $255-$265M, can its momentum withstand rising competition?",
    "url": "https://finance.yahoo.com/news/tavalisse-continue-drive-rigel-pharmaceuticals-131200351.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "1d576e80-082a-3edc-9e2a-bd9c473dec4f",
      "content": {
        "id": "1d576e80-082a-3edc-9e2a-bd9c473dec4f",
        "contentType": "STORY",
        "title": "Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026?",
        "description": "",
        "summary": "RIGL's 2025 sales jump 60% to $232M, led by Tavalisse. With 2026 product sales seen at $255-$265M, can its momentum withstand rising competition?",
        "pubDate": "2026-02-18T13:12:00Z",
        "displayTime": "2026-02-18T13:12:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tavalisse-continue-drive-rigel-pharmaceuticals-131200351.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tavalisse-continue-drive-rigel-pharmaceuticals-131200351.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RIGL"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]